Proto-Oncogene Proteins c-mdm2
"Proto-Oncogene Proteins c-mdm2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.
| Descriptor ID |
D051736
|
| MeSH Number(s) |
D08.811.464.938.750.562 D12.776.624.664.700.185 D12.776.660.764
|
| Concept/Terms |
Proto-Oncogene Proteins c-mdm2- Proto-Oncogene Proteins c-mdm2
- Proto Oncogene Proteins c mdm2
- c-mdm2, Proto-Oncogene Proteins
- Mdm2 Protein
- Double Minute 2 Protein
- c-mdm2 Proto-Oncogene Protein
- Proto-Oncogene Protein, c-mdm2
- c mdm2 Proto Oncogene Protein
- Murine Double Minute 2 Protein
- Mdm-2 Protein
- Mdm 2 Protein
- MDMX Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-mdm2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-mdm2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-mdm2" by people in this website by year, and whether "Proto-Oncogene Proteins c-mdm2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 4 | 3 | 7 |
| 2011 | 3 | 1 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 6 | 6 |
| 2014 | 2 | 3 | 5 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 0 | 2 |
| 2020 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-mdm2" by people in Profiles.
-
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma. Sci Transl Med. 2025 Feb 19; 17(786):eadn6274.
-
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453.
-
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901.
-
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29.
-
Chemopreventive Agent 3,3'-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells. Int J Mol Sci. 2020 Jun 30; 21(13).
-
MDM2 and MDMX promote ferroptosis by PPARa-mediated lipid remodeling. Genes Dev. 2020 04 01; 34(7-8):526-543.
-
Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 05; 40(3):856-880.
-
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167.
-
Protein phosphatase 5 and the tumor suppressor p53 down-regulate each other's activities in mice. J Biol Chem. 2018 11 23; 293(47):18218-18229.
-
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 10 01; 78(19):5656-5667.